Washington, DC, Aug. 15, 2017 -- The Patient-Centered Outcomes Research Institute's (PCORI) Board of Governors today approved more than $115 million to fund 20 comparative clinical effectiveness research (CER) studies on a range of conditions that impose high burdens on patients, their families and the healthcare system. The Board also approved $4 million to support four projects focused on improving methods for conducting CER.
|
|||
Two of the new awards, totaling nearly $10 million, will fund studies on the most effective ways to prevent unsafe prescribing of opioids in primary care for people with acute or chronic pain. Seven awards, totaling nearly $74 million, will fund studies on the most effective approaches to care planning and delivery of palliative care to adults with advanced illnesses and their caregivers.
The awards are designed to fill vital evidence gaps about treatment and prevention on multiple topics and conditions, including:
- A Dana-Farber Cancer Institute project that will compare the benefits and risks of new, shorter courses of radiation therapy versus conventional, longer courses of radiation therapy among women with breast cancer who are undergoing breast removal and reconstruction surgery.
- A University of Southern California project in patients with Alzheimer’s disease or dementia in nursing homes that compares how well two care strategies for nondrug approaches to agitation or aggressive behavior reduce medication requirements.
- A University of Florida project comparing the effectiveness of a weight-loss maintenance program culturally tailored to African-American women versus a standard weight-loss maintenance program.
- A University of California, San Francisco, project involving patients with cancer to compare the effectiveness of acupuncture, pain counseling or both therapies, as additions to pain medication.
“These new studies will undertake urgently needed research on key questions identified with input from patients, family caregivers, clinicians and other healthcare stakeholders,” said PCORI Executive Director Joe Selby, MD, MPH. “We’re excited to expand our portfolio of patient-centered CER and look forward to seeing results from these studies. The findings will hopefully lead to improvements in practice and ultimately, better outcomes for patients and their families.”
With these latest awards, PCORI’s Board has approved $1.7 billion in funding since 2012 for more than 600 patient-centered CER studies and other projects to enhance the methods and infrastructure of CER.
The awards on opioids and palliative care resulted from two targeted funding announcements that PCORI issued in response to input from the healthcare community. PCORI hosted a series of multi-stakeholder workshops that brought together patients and representatives of groups advancing research on these conditions, as well as clinicians, government agencies, industry and health insurers to refine the questions that became the focus of the funding announcements.
The other 15 CER studies and methods projects resulted from responses to funding announcements issued under PCORI's National Priorities for Research.
Details of all approved studies can be found on PCORI’s website. The new awards were approved pending a business and programmatic review by PCORI staff, followed by issuance of formal award contracts.
The approved studies were selected through a competitive review process in which patients, caregivers and other stakeholders joined scientists in evaluating proposals using criteria including scientific merit, how well the projects engage patients and other stakeholders, and methodological rigor.
####
About PCORI
The Patient-Centered Outcomes Research Institute (PCORI) is an independent nonprofit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/75b3b725-11a1-4538-95ee-47c970a914cc
Mary McNamara Patient-Centered Outcomes Research Institute 202-370-9480 [email protected]


Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 



